Fosun Pharma

Fosun Pharma: Carbon Emissions and Climate Commitments

Fosun Pharma, headquartered in China, operating within the "Other business services (74)" industry, has reported its greenhouse gas emissions and outlined climate commitments. The company has disclosed Scope 1, 2, and 3 emissions data for several years.

In the reporting year 2024, Fosun Pharma reported a total of approximately 929,435,000 kg CO2e. This comprised approximately 184,016,000 kg CO2e for Scope 1 emissions, 653,644,000 kg CO2e for Scope 2 emissions, and 91,775,000 kg CO2e for Scope 3 emissions.

For the reporting year 2023, the company's total emissions were approximately 960,864,000 kg CO2e, with Scope 1 emissions at approximately 210,819,000 kg CO2e, Scope 2 at approximately 677,874,000 kg CO2e, and Scope 3 at approximately 72,171,000 kg CO2e.

Fosun Pharma has set near-term intensity reduction targets. By 2025, the company aims to reduce its comprehensive energy consumption intensity by 10% compared to 2020 levels, targeting 2.287 GJ/RMB10,000 revenue. Furthermore, a 15% reduction in carbon emission intensity for Scope 2 is targeted for 2025, relative to 2020, aiming for 0.23 tonnes/RMB10,000 revenue. These targets are also referenced in reports from 2022.

In addition to these specific intensity targets, Fosun Pharma notes the International Energy Agency's proposal to achieve net-zero emissions by 2050, indicating a long-term strategic consideration for net-zero goals.

Fosun Pharma's emissions data is not cascaded from a parent organisation.